MTAP and malignant mesothelioma: A prior study using a monoclonal anti-MTAP primary antibody reported acceptable specificity and sensitivity for MTAP immunohistochemistry in detecting the CDKN2A homozygous deletion and diagnosis of malignant mesothelioma (24).